Nagapetir represents a novel medical approach targeting activated protein C, a crucial element in the clotting cascade. This agent functions as a targeted enzyme suppressor, demonstrating promise in reducing thrombotic events. Preclinical investigations have shown encouraging outcomes, suggesting